BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China (BeiGene Ltd)

Edit Public Technologies 05 Jul 2016
(NASDAQ.BGNE), a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of the first patient in China in a Phase I clinical trial of BGB-3111, an investigational Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various B-cell malignancies....

Russia's BTK Group studying prospects of co-op with Turkmenistan

Edit Topix 04 Jul 2016
Russia's BTK Holding, one of the country's largest holdings of light industry, is discussing the prospects of mutually beneficial cooperation with Turkmenistan, Neutral Turkmenistan newspaper reported. BTK Group has its own high technology production base comprising enterprises in Russia's Saint Petersburg, Leningrad Region , Rostov Region , Bryansk ......

BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 (BeiGene Ltd)

Edit Public Technologies 29 Jun 2016
WALTHAM, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of the first patient in a Phase I clinical trial of BGB-3111, a Bruton's tyrosine kinase (BTK) inhibitor, in combination with BGB-A317, a PD-1 antibody, for the treatment of various B-cell malignancies....

BRIEF-Beigene announces initiation of a combination trial

Edit Reuters 29 Jun 2016
* Beigene announces initiation of a combination trial of the BTK inhibitor BGB-3111 with the PD-1 antibody BGB-a317 Source text for Eikon. Further company coverage. (Bengaluru Newsroom. +1-646-223-8780) ....

Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD) (Johnson & Johnson)

Edit Public Technologies 29 Jun 2016
(Source ... Bruton's tyrosine kinase and interleukin-2-inducible T-cell kinase, known as BTK and ITK respectively ... IMBRUVICA works by blocking a specific protein called Bruton's tyrosine kinase (BTK). The BTK protein transmits important signals that tell B cells to mature and produce antibodies and is needed by specific cancer cells to multiply and spread. IMBRUVICA targets and blocks BTK, inhibiting cancer cell survival and spread ... ... # # #....

Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration (Infinity Pharmaceuticals Inc)

Edit Public Technologies 28 Jun 2016
At this time, Infinity is continuing to focus resources on the DYNAMO and DUO studies, as well as SYNCHRONY, a combination study of duvelisib plus obinutuzumab in CLL or small lymphocytic lymphoma patients who were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor and FRESCO, a combination study in patients with relapsed/refractory ......

‘American Gothic’ hits close to home for BTK’s daughter

Edit The Wichita Eagle 24 Jun 2016
A new television show appears to reference the BTK serial murder case. Dennis Rader, calling himself BTK, killed ten people in and around Wichita. His daughter says she and her family will never escape her father’s legacy ... ....

‘American Gothic’ hits close to home for serial killer’s daughter

Edit The State 24 Jun 2016
A new television show appears to reference the BTK serial murder case. Dennis Rader, calling himself BTK, killed ten people in and around Wichita. His daughter says she and her family will never escape her father’s legacy ... ....

‘American Gothic’ hits close to home for killer’s daughter

Edit The Miami Herald 24 Jun 2016
American Gothic,” a new CBS show this summer, is about a serial killer “S.B.K.” and possibly the killer’s family ... That sounds much like the story of Dennis Rader of Park City, who in 2005 was arrested and identified as the serial killer BTK, who operated in Wichita from 1974 to 2005 ... ... Kerri Rawson, daughter of ‘BTK’ killer Dennis Rader ....

Daughter of serial killer BTK speaks out on TV show

Edit CBS News 24 Jun 2016
Article extract not available. Link to source for the full article. ....

Aptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders

Edit Stockhouse 21 Jun 2016
SAN DIEGO and TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc ... On June 8, 2016 Aptose and CrystalGenomics, Inc. announced an exclusive global option and license agreement focused on the development of CG026806 (CG’806), a first-in-class, highly potent, non-covalent small molecule inhibitor of the Bruton’s tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK) ... About Aptose ...   ... ....

Aptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders (Aptose Biosciences Inc)

Edit Public Technologies 21 Jun 2016
(Source. Aptose Biosciences Inc). SAN DIEGO and TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc ... announced an exclusive global option and license agreement focused on the development of CG026806 (CG'806), a first-in-class, highly potent, non-covalent small molecule inhibitor of the Bruton's tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK) ... About Aptose ... Aptose Biosciences Inc ... (noodl....

MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of Currently 26 Months under MOR208 Treatment (MorphoSys AG)

Edit Public Technologies 17 Jun 2016
In addition, at the ASCO 2016 Annual Meeting the trial design of a phase 2 study with MOR208 was presented which trial is planned to evaluate MOR208 in combination with idelalisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients no longer responding to or no longer tolerating Bruton's tyrosine kinase (BTK) inhibitor therapy (e.g....
×